Clinical trials: Cirrhosis Liver
Pleural Effusion, Heart Failure
Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
- Conditions
- Pleural Effusion, Heart Failure, Malignant Neoplasm, Fluid Overload
- Trial name
- NCT05797649
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive
Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
Patients with cirrhosis are particularly prone to infection which is frequently a precipitant of hepatic encephalopathy, renal failure and circulatory collapse.
- Trial name
- RIFSYS (NCT02019784)
- Testing
- Rifaximin-α
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- King's College Hospital NHS Trust
Liver Fibrosis, MRI
Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI
Quantification of hepatic fibrosis by IVIM sequences in 1.5T MRI.
- Conditions
- Liver Fibrosis, MRI, IVIM, Liver Biopsy
- Trial name
- IVIM-MRI (NCT03173287)
- Testing
- Quantification of liver fibrosis
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Clermont-Ferrand
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms.
- Trial name
- NCT06773221
- Testing
- Chiglitazar 64mg
- Where
- 4 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing Friendship Hospital
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Ascites, Hepatic Cirrhosis
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.
- Trial name
- NCT01349348
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 535 people
- Sponsor
- Otsuka Beijing Research Institute
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Liver Fibrosis
T1rho Imaging of Liver in Presence of Iron
Liver T1rho is elevated in response to accumulation of extracellular matrix proteins during fibrosis. The presence of hepatic iron overload; however, can shorten the T1rho value.
- Trial name
- NCT05154643
- Where
- Hong Kong
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Liver Diseases, Liver Fibrosis
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
- Conditions
- Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis
- Trial name
- NCT03479125
- Testing
- Ultrasound
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatitis C
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C.
- Trial name
- NCT03318887
- Testing
- Sofosbuvir/daclatasvir with or without ribavirin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Hospices Civils de Lyon
Compensated Cirrhosis and Portal Hypertension
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
The main purpose of this exploratory study was to investigate the effect of serelaxin (RLX030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertension.
- Trial name
- NCT01640964
- Testing
- Terlipressin acetate, Serelaxin (RLX030)
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Fatigue, Primary Biliary Cirrhosis
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
Primary Biliary Cirrhosis (PBC) is a liver disease that predominantly affects females, can present for the first time at any age and which develops over many years.
- Trial name
- RITPBC (NCT02376335)
- Testing
- Rituximab
- Where
- United Kingdom
- Volunteers
- 71 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Cirrhosis
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD.
- Trial name
- NCT01212250
- Testing
- carvedilol
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HEPATITIS B CHRONIC, Cirrhosis, Liver
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort.
- Conditions
- HEPATITIS B CHRONIC, Cirrhosis, Liver, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07544121
- Testing
- Babao Dan Capsule, Babao Dan Capsule simulant
- Volunteers
- 1,034 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma, Liver Cancer
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
Intro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Cirrhosis, Chronic Liver Disease
- Trial name
- FASTRAK (NCT05095714)
- Testing
- Liver ultrasound and fast-MRI, Liver ultrasound
- Where
- France
- Volunteers
- 944 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Cirrhosis
Intravenous Interferon During Liver Transplant
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation.
- Trial name
- NCT01192698
- Testing
- IV interferon
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Liver Cirrhosis, Liver Fibrosis
Functional MRI to Determine Severity of Cirrhosis
This is a pilot study to investigate the feasibility of a novel MRI technique to assess the severity of liver cirrhosis and predict complications based on functionality and perfusion measurements whilst maintaining image quality.
- Trial name
- NCT03623360
- Testing
- Free breathing DCE-MRI
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Leeds
Decompensated Cirrhosis
CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and…
- Trial name
- NCT05045924
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Liver Cirrhosis, Ascites Hepatic
Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
Large volume paracentesis with albumin administration is the standard of care for patients with refractory ascites complicating end-stage liver disease.
- Trial name
- NCT03202524
- Testing
- Fresh Frozen Plasma (FFP), Albumin
- Sponsor
- Montefiore Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.